Somnomed Limited (AU:SOM)
ASX:SOM
SOM Stock Chart & Stats
AU$0.60
AU$0.03(6.67%)
At close: 4:00 PM EST
AU$0.60
AU$0.03(6.67%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$0.95
Previous CloseN/A
Volume51.81K
Average Volume (3M)705.41K
Market Cap
AU$122.69M
Enterprise ValueAU$118.67M
Total Cash (Recent Filing)AU$18.03M
Total Debt (Recent Filing)AU$14.01M
Price to Earnings (P/E)52.9
Beta1.41
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,083,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.99Price Target Upside65.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSomnomed has delivered durable top-line expansion, with revenue growth consistently positive. Sustained revenue growth signals widening clinician adoption and market penetration for oral appliance therapy, underpinning longer-term scale economics and supporting reinvestment in sales and product development.
Strong Cash GenerationA dramatic improvement in free cash flow and positive operating cash flow versus net income demonstrate the company’s ability to convert sales into cash. This cash resilience reduces refinancing risk, funds working capital and targeted growth initiatives, and gives time to fix profitability structurally.
Conservative Leverage And Healthy Unit EconomicsLow debt levels paired with a high gross margin indicate strong unit economics and financial flexibility. Conservative leverage lowers solvency risk while ~60% gross margins provide room to cover SG&A and invest in clinician education or distribution, supporting sustainable margin recovery as sales scale.
Bears Say
Persistent UnprofitabilityDespite revenue and gross margins, the company reports negative EBIT and net margins, showing operating cost structure or scale issues. Continued losses constrain retained earnings, limit dividend capacity, and require either efficiency gains or higher sales growth to produce sustainable net profitability.
Low Return On EquityA negative ROE indicates the business is not delivering returns on shareholders’ capital. Even with low leverage, poor ROE signals inefficient capital deployment or immature profitability, which can pressure investor confidence and necessitates clearer plans to translate cash generation into positive shareholder returns.
Revenue Exposure To Clinician Adoption And ReimbursementRevenue depends heavily on dentist/sleep-clinic adoption, referral flows and reimbursement/patient-pay dynamics. These external factors create structural demand variability and regulatory/reimbursement risk, meaning growth relies on continued clinician engagement and favourable payer environments.
Somnomed Limited News
SOM FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest share price was AU$0.37 and its highest was AU$0.94 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is AU$122.69M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,083,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in AU:SOM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.28%
12-Months-Change
Fundamentals
Return on Equity
-5.31%
Trailing 12-Months
Asset Growth
14.75%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obstructive sleep apnea; SomnoBrux, a dental guard for the treatment of teeth grinding damage; SomMorning Repositioner, which help return mandible back to its pre-treatment centric position; and SomTabs for cleaning oral devices. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
SOM Company Deck
SOM Earnings Call
Q2 2026
0:00 / 0:00
SOM Stock 12 Month Forecast
Average Price Target
AU$0.99
▲(65.81% Upside)
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---